Company to receive up to $5M from Roswell Park Cancer Institute and various New York agencies.
Cleveland BioLabs is partnering with Roswell Park Cancer Institute to develop the company’s cancer and radio-protectant drug candidates.
Under the strategic research partnership, Cleveland BioLabs will establish a research and clinical facility at the Roswell Park campus in Buffalo, NY, which will become the foundation for its advanced research and clinical trials.
Roswell Park and various agencies of the state of New York will provide Cleveland BioLabs with up to $5 million of nondilutive funding. The company will have an open-ended license to any basic research conducted within or in collaboration with its Roswell Park laboratory.
